Yondelis is developed by PharmaMar (pharmamar.com) in partnership with Johnson & Johnson Pharmaceutical Research & Development. PharmaMar will market Yondelis in Europe while Tibotec Therapeutics, a division of Ortho Biotech Products LP, will market the drug in the United States and Ortho Biotech, a division of Janssen-Cilag NV (janssen-cilag.com), will market the drug in the rest of the world.
TARLATAMAB YA ES EL NUEVO TRATAMIENTO ESTÁNDAR DE SEGUNDA LINEA SMALL CELL LUNG CANCER EXTENSIVE-STAGE ... PARECE EVIDENTE QUE TARLATAMAB PODRÍA SER EL NUEVO PARADIGMA EN TODAS LAS LÍNEAS DE TRATAMIENTO SCLC-ES INCLUIDA LA DE MANTENIMIENTO ... EN LA QUE YA ESTÁ EN PLENA FASE III COMBINADO CON ATEZOLIZUMAB DE ROCHE ... Y ADEMÁS CUENTA CON EL STATUS DE ORPHAN DRUG EN ESTADOS UNIDOS .
26 marzo 2008
Yondelis no solo estara a la Venta en Europa ( EMEA ) y EEUU ( FDA ) . J&J lo quiere vender en "" Todo el Mundo "" .
Yondelis is developed by PharmaMar (pharmamar.com) in partnership with Johnson & Johnson Pharmaceutical Research & Development. PharmaMar will market Yondelis in Europe while Tibotec Therapeutics, a division of Ortho Biotech Products LP, will market the drug in the United States and Ortho Biotech, a division of Janssen-Cilag NV (janssen-cilag.com), will market the drug in the rest of the world.